Entity

Time filter

Source Type

Halifax, Canada

Fraker M.A.,TerraMar Environmental Research Ltd | Brown R.G.,Immunovaccine
Wildlife Research | Year: 2011

In reporting the results of a trial of contraceptive vaccines in wild horses, Gray et al. (2010) misidentified one of the vaccines as SpayVac®, a porcine zona pellucida (pZP) vaccine that owes its typically very high efficacy to a special DepoVax® liposome technology. We believe that the absence of DepoVax liposomes ought to have been considered as a possible explanation for the unexpectedly low efficacy that was observed. © 2011 CSIRO. Source


The present invention is concerned with vaccines and their preparation. An effective long-term immune response, especially in mammals, can be produced using a vaccine comprising an antigen encapsulated in liposomes, a suitable adjuvant and a carrier comprising a continuous phase of a hydrophobic substance. The vaccine is particularly effective in eliciting the production of antibodies that recognize epitopes of native proteins.


The invention provides compositions comprising liposomes, an antigen capable of inducing a humoral immune response, a carrier comprising a continuous phase of a hydrophobic substance, and an adjuvant that activates or increases the activity of TLR2. The invention also provides uses for such compositions in inducing a humoral response and methods for their use in the treatment of a disease, disorder or ailment ameliorated by a humoral immune response.


The invention compositions comprising a continuous hydrophobic phase and liposomes as a vehicle for delivery of an antigen capable of inducing a cytotoxic T lymphocyte (CTL) response and methods for their use in the treatment of cancer.


Karkada M.,Immunovaccine | Karkada M.,Dalhousie University | Weir G.M.,Immunovaccine | Quinton T.,Immunovaccine | And 2 more authors.
Vaccine | Year: 2010

Nucleic acid vaccines represent a promising alternative to killed bacterial antigen, recombinant protein or peptide vaccines for infectious diseases and cancer immunotherapy. Although significant advances are made with DNA vaccines in animal studies, there are severe limitations to deliver these vaccines effectively and considerable reservations exist about current methods used. In this study, a liposome-based vaccine platform, VacciMax® (VM), and its modified water-free version, DepoVax™ (DPX), were tested for their ability to improve in vivo delivery of plasmid DNA (pDNA), mRNA and siRNA. Subcutaneously injected pDNA for IL12 and pDNA as well as mRNA for green fluorescent protein (GFP) in VM/DPX significantly enhanced their in vivo expression. Enhanced IL12 secretion and GFP expression was restricted to CD11b+ and CD11c+ antigen-presenting cells, but not B cells. Further, significant inhibition of plasmid/antigen-induced IL12 secretion was seen after injection of IL12-siRNA in VM. These findings suggest VM and DPX to be promising means of delivering nucleic acid vaccines in vivo, and warrant further studies on their role in inducing effective immune responses. © 2010 Elsevier Ltd. Source

Discover hidden collaborations